The incidence of tickborne infections in the United States has risen significantly within the past decade. It is imperative, therefore, that public health officials and scientists build a robust understanding of pathogenesis, design improved diagnostics, and develop preventive vaccines, according to a new commentary in the New England Journal of Medicine from leading scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Tickborne Diseases News Releases
Crimean-Congo hemorrhagic fever (CCHF) is a viral disease spread by ticks in the Middle East, Asia, Africa and parts of Europe. Infection with CCHF virus is fatal in nearly one of every three cases. No specific treatments or vaccines for CCHF exist, primarily because a suitable animal model for studying the disease has not been available. Scientists have used mice to study CCHF but had to weaken their immune systems to cause infection. Studies in larger animals have not consistently replicated human disease.
While rare, some people experience recurrent episodes of anaphylaxis—a life-threatening allergic reaction that causes symptoms such as the constriction of airways and a dangerous drop in blood pressure—for which the triggers are never identified. Recently, researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, found that some patients’ seemingly inexplicable anaphylaxis was actually caused by an uncommon allergy to a molecule found naturally in red meat.
National Institutes of Health (NIH) scientists have filled a research gap by developing a laboratory model to study ticks that transmit flaviviruses, such as Powassan virus. Powassan virus was implicated in the death of a New York man earlier this year. The unusual model involves culturing organs taken from Ixodes scapularis ticks and then infecting those organ cultures with flaviviruses, according to researchers at Rocky Mountain Laboratories, part of NIH’s National Institute of Allergy and Infectious Diseases (NIAID).